transmembrane protein 216Genealiases: HSPC244 · RP98
Q-omics provides the consensus-scored TMEM216 profile across patient tissues and cancer cell-line models. TMEM216 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TMEM216 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, TMEM216 RNA expression shows 18,983 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, BLCA, and ACC as cancer lineages where TMEM216 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM216 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM216 survival associations across molecular data types. TMEM216 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM216 RNA expression–survival associations across cancer types. High TMEM216 expression shows unfavorable associations in KIRP, ACC, LIHC, DLBC and PAAD, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TMEM216 RNA expression.
This table summarizes TMEM216 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM216. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM216 shows lower tumor expression in KICH and higher tumor expression in BLCA, COAD, LUAD, LIHC and HNSC. The BLCA box plot shows higher TMEM216 RNA expression in tumor versus normal tissue (log2 FC = +1.007, t-test p < 0.001).
This table shows molecular features associated with TMEM216 in patient tissues and cancer cell lines. In patient samples, TMEM216 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM216 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
